Poster Session：PS 0232 ; Gastroenterology : Effect of Metformin in the Treatment of Nonalcoholic Fatty Liver Disease-A Meta Analysis on Chinese Clinical Trials

Background: Nonalcoholic fatty liver disease (NAFLD) is currently the most common liver disease worldwide, with increasing prevalence in China as well. Nevertheless, the pathogenesis of NAFLD is still unclear, where the participation of insulin resistance is well acknowledge. As one type of insulin-sensitizing agent, metformin is theoretically useful in NAFLD therapy but the clinical data from china is lacking. In this study, we systematically analyzed the effect of Metformin in treating NAFLD. Methods: Randomized controlled trials conducted in China and published between January 2000 to December 2013 were screened from Chinese biomedicine web database and Chinese scientifi c journals database using proper MESH headings, followed by assessment from two independent investigators according to established inclusion criteria. The characteristics of chosen articles were displayed for further analysis while the primary and secondary end point were set as alleviation of metabolic parameters and hepatocyte lipid accumulation, respectively. The summary odds ratio was calculated to determine the overall effect of metformin in NAFLD therapy. All the data were entered and analyzed using REVIEW MANAGER 4.1, and p<0.05 was defi ned as statistically signifi cant in all analysis. Results: Eight qualifi ed trials were enrolled and the summary odds ratio for effective therapy on NAFLD was 3.34 (95% CI: 2.57, 4.56, p<0.01). The difference in the follow- up period did not infl uence the fi nal outcomes. Conclusions: Metformin therapy is effective in treating NAFLD patients in China.